Predicting MEK Inhibitor Response in Lung Cancer: A Proper Signature Is Required

Clin Cancer Res. 2017 Mar 15;23(6):1365-1367. doi: 10.1158/1078-0432.CCR-16-2576. Epub 2016 Dec 6.

Abstract

The ERK signaling pathway is one of the most commonly deregulated pathways in cancer. Assays that accurately measure ERK signaling output in clinical specimens would be extremely helpful not only in determining the pharmacodynamic effects of drug treatment but also in selecting those patients most likely to respond to therapy. Clin Cancer Res; 23(6); 1365-7. ©2016 AACRSee related article by Brant et al., p. 1471.

MeSH terms

  • Apoptosis / drug effects
  • Cell Proliferation / drug effects
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • MAP Kinase Signaling System / drug effects*
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins p21(ras) / genetics

Substances

  • KRAS protein, human
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins p21(ras)